Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BMS986158 |
| Synonyms | |
| Therapy Description |
BMS986158 is BET inhibitor, which interferes with chromatin remodeling to prevent gene expression and tumor growth (PMID: 32286255). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BMS986158 | BMS-986158|BMS 986158 | BET Inhibitor (Pan) 33 | BMS986158 is BET inhibitor, which interferes with chromatin remodeling to prevent gene expression and tumor growth (PMID: 32286255). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04817007 | Phase I | BMS986158 + Ruxolitinib BMS986158 + CYC065 BMS986158 | A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) | Active, not recruiting | USA | ROU | POL | ITA | ISR | HUN | GRC | FRA | ESP | DEU | AUS | 1 |
| NCT03936465 | Phase I | BMS986158 CC-90010 | Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer | Completed | USA | CAN | 0 |
| NCT02419417 | Phase Ib/II | BMS986158 Paclitaxel | Study of BMS-986158 in Subjects With Select Advanced Solid Tumors | Completed | USA | FRA | ESP | CAN | AUS | 0 |